Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Phase 3

Recruiting

Conditions: Acute Treatment of Migraine

Interventions: Drug: Rimegepant (PF-07899801)

First Posted Date: 2021-02-08

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT04743141

Locations: 🇺🇸
Perseverance Research Center, LLC, Scottsdale, Arizona, United States
🇺🇸
Physicians Research Group, Tempe, Arizona, United States
🇺🇸
Advanced Research Center, Inc., Anaheim, California, United States

and more 108 locations

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

Completed

Conditions: Breast Cancer

First Posted Date: 2021-02-03

Last Posted Date: 2024-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT04735367

Locations: 🇯🇵
Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan
🇯🇵
National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan
🇯🇵
Kyoto University Hospital, Kyoto, Japan

and more 10 locations

Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Device: Wearable device

First Posted Date: 2021-02-03

Last Posted Date: 2024-11-22

Lead Sponsor: Pfizer

Target Recruit Count: 99

Registration Number: NCT04736576

Locations: 🇯🇵
Toranomon Hospital, Minato, Tokyo, Japan
🇯🇵
Saitama Cancer Center, Kita-adachi-gun, Saitama, Japan
🇯🇵
Hokkaido Cancer Center, Sapporo, Hokkaido, Japan

and more 17 locations

Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Conditions: Sickle Cell Disease

First Posted Date: 2021-01-26

Last Posted Date: 2024-11-20

Lead Sponsor: Pfizer

Registration Number: NCT04724421

Locations: 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸
Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States

and more 34 locations

A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Tucatinib
Biological: Trastuzumab
Drug: Capecitabine

First Posted Date: 2021-01-25

Last Posted Date: 2025-05-28

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT04721977

Locations: 🇰🇷
Seoul National University Hospital ( Site 2003), Seoul, Korea, Republic of
🇯🇵
National Cancer Center Hospital ( Site 1003), Tokyo, Japan
🇯🇵
Fukushima Medical University Hospital ( Site 1012), Fukushima, Japan

and more 25 locations

A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2021-01-25

Last Posted Date: 2023-09-29

Lead Sponsor: Pfizer

Target Recruit Count: 1712

Registration Number: NCT04721808

Locations: 🇺🇸
Pfizer, New York, New York, United States

Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

Completed

Conditions: Arthritis Rheumatoid

Interventions: Drug: Tofacitinib

First Posted Date: 2021-01-25

Last Posted Date: 2024-04-12

Lead Sponsor: Pfizer

Target Recruit Count: 7807

Registration Number: NCT04721821

Locations: 🇺🇸
Pfizer, New York, New York, United States

Korea Post Marketing Surveillance (PMS) Study of Vizimpro

Conditions: Lung Neoplasms

Interventions: Drug: Vizimpro

First Posted Date: 2021-01-22

Last Posted Date: 2025-06-03

Lead Sponsor: Pfizer

Target Recruit Count: 187

Registration Number: NCT04721106

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Etrasimod

First Posted Date: 2021-01-13

Last Posted Date: 2023-10-16

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT04706793

Locations: 🇯🇵
Kojunkai Daido Clinic, Nagoya-shi, Aichi-ken, Japan
🇯🇵
Ishii Eye Clinic, Nagareyama-shi, Chiba, Japan
🇯🇵
Fukuoka University Hospital, Fukuoka-shi, Fukuoka, Japan

and more 35 locations

A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: PF-06882961 (Cohort 3)
Drug: PF-06882961 (Cohorts 1 and 2)
Drug: Placebo (Cohorts 1 and 2)
Drug: Placebo (Cohort 3)

First Posted Date: 2021-01-13

Last Posted Date: 2024-11-05

Lead Sponsor: Pfizer

Target Recruit Count: 628

Registration Number: NCT04707313

Locations: 🇺🇸
PMG Research, Inc. d/b/a PMG Research of Knoxville, Knoxville, Tennessee, United States
🇨🇦
Rivergrove Medical Clinic, Winnipeg, Manitoba, Canada
🇨🇦
Aggarwal and Associates Limited, Brampton, Ontario, Canada

and more 37 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy